2016 Q1 Form 10-Q Financial Statement
#000156459016018694 Filed on May 10, 2016
Income Statement
| Concept | 2016 Q1 | 2015 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $13.21M | $4.140M |
| YoY Change | 219.08% | 108.04% |
| % of Gross Profit | ||
| Research & Development | $40.42M | $17.36M |
| YoY Change | 132.75% | 107.95% |
| % of Gross Profit | ||
| Depreciation & Amortization | $544.0K | $201.0K |
| YoY Change | 170.65% | 71.79% |
| % of Gross Profit | ||
| Operating Expenses | $53.62M | $21.50M |
| YoY Change | 149.38% | 107.97% |
| Operating Profit | -$53.62M | -$21.50M |
| YoY Change | 149.38% | 107.97% |
| Interest Expense | $980.0K | $270.0K |
| YoY Change | 262.96% | 200.0% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $865.0K | $123.0K |
| YoY Change | 603.25% | -103.74% |
| Pretax Income | -$52.76M | -$21.38M |
| YoY Change | 146.77% | 56.86% |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$52.76M | -$21.38M |
| YoY Change | 146.77% | 56.85% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$1.354M | -$628.6K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 38.98M | 34.01M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2016 Q1 | 2015 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $411.9M | $342.6M |
| YoY Change | 20.23% | 107.13% |
| Cash & Equivalents | $70.76M | $178.0M |
| Short-Term Investments | $341.1M | $164.5M |
| Other Short-Term Assets | $18.40M | $8.000M |
| YoY Change | 130.0% | 90.48% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $430.2M | $350.5M |
| YoY Change | 22.74% | 106.62% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $13.40M | $3.500M |
| YoY Change | 282.86% | 96.96% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $75.90M | |
| YoY Change | ||
| Other Assets | $4.600M | $1.800M |
| YoY Change | 155.56% | 227.27% |
| Total Long-Term Assets | $94.00M | $5.300M |
| YoY Change | 1673.58% | 72.58% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $430.2M | $350.5M |
| Total Long-Term Assets | $94.00M | $5.300M |
| Total Assets | $524.2M | $355.8M |
| YoY Change | 47.33% | 106.01% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $6.000M | $5.800M |
| YoY Change | 3.45% | 65.95% |
| Accrued Expenses | $23.60M | $8.400M |
| YoY Change | 180.95% | 159.42% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $29.90M | $14.20M |
| YoY Change | 110.56% | 108.49% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $4.480M | $500.0K |
| YoY Change | 796.0% | 150.0% |
| Total Long-Term Liabilities | $4.480M | $500.0K |
| YoY Change | 796.0% | 150.0% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $29.90M | $14.20M |
| Total Long-Term Liabilities | $4.480M | $500.0K |
| Total Liabilities | $34.36M | $14.70M |
| YoY Change | 133.74% | 110.0% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $489.8M | $341.1M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $524.2M | $355.8M |
| YoY Change | 47.33% | 106.02% |
Cashflow Statement
| Concept | 2016 Q1 | 2015 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$52.76M | -$21.38M |
| YoY Change | 146.77% | 56.85% |
| Depreciation, Depletion And Amortization | $544.0K | $201.0K |
| YoY Change | 170.65% | 71.79% |
| Cash From Operating Activities | -$44.90M | -$17.66M |
| YoY Change | 154.25% | 111.85% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $1.477M | $459.0K |
| YoY Change | 221.79% | -19.33% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $23.25M | -$3.610M |
| YoY Change | -744.04% | -94.43% |
| Cash From Investing Activities | $21.78M | -$4.070M |
| YoY Change | -635.14% | -93.78% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $314.0K | $175.4M |
| YoY Change | -99.82% | 36.65% |
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 310.0K | 175.4M |
| YoY Change | -99.82% | 44.09% |
| NET CHANGE | ||
| Cash From Operating Activities | -44.90M | -17.66M |
| Cash From Investing Activities | 21.78M | -4.070M |
| Cash From Financing Activities | 310.0K | 175.4M |
| Net Change In Cash | -22.81M | 153.7M |
| YoY Change | -114.84% | 220.1% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$44.90M | -$17.66M |
| Capital Expenditures | $1.477M | $459.0K |
| Free Cash Flow | -$46.38M | -$18.12M |
| YoY Change | 155.96% | 103.47% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
7373000 | |
| CY2016Q1 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
1291000 | |
| CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
450207000 | |
| CY2015Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
13060000 | |
| CY2015Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
2135000 | |
| CY2015Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
150000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
960000 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-51797000 | |
| CY2015Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-21299000 | |
| CY2016Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
544000 | |
| CY2015Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
201000 | |
| CY2016Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-1828000 | |
| CY2015Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-965000 | |
| CY2015Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2408000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
4028000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
948000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
1468000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
7000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
2638000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
437000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-1869000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
664000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-44895000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-17659000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1477000 | |
| CY2015Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
459000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
118130000 | |
| CY2015Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
77254000 | |
| CY2016Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
11494000 | |
| CY2015Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
12766000 | |
| CY2016Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
131431000 | |
| CY2015Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
62240000 | |
| CY2016Q1 | us-gaap |
Increase In Restricted Cash
IncreaseInRestrictedCash
|
1543000 | |
| CY2015Q1 | us-gaap |
Increase In Restricted Cash
IncreaseInRestrictedCash
|
1358000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
21775000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-4065000 | |
| CY2016Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
314000 | |
| CY2015Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
175440000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
314000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
175440000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-22806000 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
153716000 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
24324000 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
178040000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
38882394 | |
| CY2016Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
250000000 | |
| CY2016Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
4480000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
38882394 | |
| CY2016Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2016Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
38992346 | |
| CY2016Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
38992346 | |
| CY2016Q1 | us-gaap |
Liabilities
Liabilities
|
34360000 | |
| CY2016Q1 | us-gaap |
Long Term Investments
LongTermInvestments
|
75932000 | |
| CY2016Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | |
| CY2015Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
99259000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
250000000 | |
| CY2016Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
17088000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
40415000 | |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
17364000 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
13207000 | |
| CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4138000 | |
| CY2016Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
53622000 | |
| CY2015Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
21502000 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-53622000 | |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-21502000 | |
| CY2016Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
984000 | |
| CY2015Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
273000 | |
| CY2016Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-119000 | |
| CY2015Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-150000 | |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
865000 | |
| CY2015Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
123000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-52757000 | |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-21379000 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.35 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.63 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38970151 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
34008830 | |
| CY2015Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
80000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
10217000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
152000 | |
| CY2016Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Organization </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ultragenyx Pharmaceutical Inc. (the Company) is a biopharmaceutical company and was incorporated in California on April 22, 2010. The Company subsequently reincorporated in the state of Delaware in June 2011. </p> <p style="margin-bottom:0pt;margin-top:4pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating metabolic genetic diseases. The Company is currently conducting a Phase 3 study of aceneuramic acid extended-release (Ace-ER) in patients with GNE myopathy, which is also known as hereditary inclusion body myopathy (HIBM), a progressive muscle-wasting disorder; a Phase 3 study of recombinant human beta-glucuronidase (rhGUS) in patients with mucopolysaccharidosis 7, or MPS 7, a rare lysosomal storage disease; a Phase 2 clinical study for UX007 in patients with glucose transporter type-1 deficiency syndrome (Glut1 DS), a brain energy deficiency; a Phase 2 clinical study of UX007 in patients severely affected by long-chain fatty acid oxidation disorders (LC-FAOD), a genetic disorder in which the body is unable to convert long chain fatty acids into energy; and Phase 2 and Phase 3 studies of KRN23, an antibody targeting fibroblast growth factor 23, or FGF23, in patients with X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), both rare diseases that impair bone mineralization. The Company operates as one reportable segment.</p> <p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p></div> | |
| CY2016Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:4pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities, and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. </p></div> | |
| CY2015Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2408000 | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4190773 | |
| CY2016Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | |
| CY2016Q1 | us-gaap |
Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
|
472908000 | |
| CY2015Q4 | us-gaap |
Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
|
514340000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
472816000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
244000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
472908000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
515208000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
11000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
879000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
514340000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2016Q1 | rare |
Research And Clinical Trial Expenses
ResearchAndClinicalTrialExpenses
|
13179000 | |
| CY2015Q4 | rare |
Research And Clinical Trial Expenses
ResearchAndClinicalTrialExpenses
|
9764000 | |
| CY2016Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5339000 | |
| CY2015Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
9423000 | |
| CY2016Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5047000 | |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
5597000 | |
| CY2016Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
10217000 | |
| CY2015Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3057053 |
